SCHEMBL4910058

SCHEMBL4910058

C[C@H]1CCN(C(=O)c2ccc(-c3ccc4[nH]ccc4c3)c(C(=O)OCc3ccncc3)c2)c2ccccc2N1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 2/20 0.39
MAPK14 Q16539 2/20 0.36
ENPP2 Q13822 1/20 0.36
GHSR Q92847 6/20 0.36
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
OXTR P30559 1/20 0.34
CYP17A1 P05093 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
ROCK2 O75116 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA7 P36544 1/20 0.32
CHRNA4 P43681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4912744 0.87 MAPK14 (0.38) GPBAR1MAPK14GHSROXTR
SCHEMBL4909403 0.86 MAPK14 (0.36) GPBAR1MAPK14GHSROXTR
SCHEMBL14432255 0.86 MAPK14 (0.36) GPBAR1MAPK14GHSROXTR
SCHEMBL14258886 0.86 KDR (0.39) GPBAR1MAPK14GHSROXTRACACB
SCHEMBL4933826 0.85 MAPK14 (0.37) GPBAR1MAPK14GHSROXTR
SCHEMBL4933816 0.85 MAPK14 (0.37) GPBAR1MAPK14GHSROXTR
SCHEMBL4910784 0.85 HRH3 (0.39) GPBAR1MAPK14GHSROXTR
SCHEMBL14258848 0.85 OXTR (0.36) GPBAR1MAPK14GHSROXTRACACB
SCHEMBL5242825 0.84 OXTR (0.40) GPBAR1MAPK14GHSROXTRACACB
SCHEMBL4908666 0.84 OXTR (0.35) GPBAR1MAPK14GHSROXTRACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
EP-1820799-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION Wakamoto Pharmaceutical Co., Ltd. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION GABRA5, GABRA1, GABRB1 GPBAR1 52/4885MAPK14 1799/4885ENPP2 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.